Insulin-like growth factor-I gene therapy reverses morphologic changes and reduces hyperprolactinemia in experimental

Gloria M Console1, Claudia B Herenu, Gisela A Camihort

  • 1Department of Cytology, Histology & Embryology B-CICBA, National University of La Plata, La Plata, Argentina. gconsole2@gmail.com

Molecular Cancer
|January 26, 2008
PubMed
Abstract

Insights

Insulin-like growth factor I (IGF-I) gene therapy effectively reduced prolactin levels and normalized pituitary tumor size in a rat model. This gene therapy approach shows promise for treating prolactinomas and other pituitary tumors.

Area of Science:

  • Endocrinology
  • Gene Therapy
  • Oncology

Background:

  • Gene therapy offers a promising alternative to traditional treatments like surgery and radiotherapy for pituitary tumors.
  • Suicide gene therapy has been the primary experimental approach for pituitary tumors to date.
  • This study investigates insulin-like growth factor I (IGF-I) gene therapy for estrogen-induced prolactinomas in rats.

Purpose of the Study:

  • To assess the efficacy of IGF-I gene therapy in treating estrogen-induced prolactinomas in a rat model.
  • To evaluate the impact of IGF-I gene therapy on prolactin levels and pituitary lactotroph morphology.

Main Methods:

  • Estrogen (E2) was used to induce prolactinomas in Sprague Dawley rats.
  • Adenoviral vectors carrying rat IGF-I (RAd-IGFI) or green fluorescent protein (RAd-GFP) were injected into the pituitary.
  • Serum prolactin (PRL) levels and pituitary lactotroph morphology (cell size and volume density) were analyzed.

Main Results:

  • RAd-IGFI administration significantly reduced elevated serum PRL levels compared to the RAd-GFP control.
  • IGF-I gene therapy reversed the E2-induced increase in lactotroph cell size.
  • The volume density of lactotrophs was also significantly reduced by RAd-IGFI treatment.

Conclusions:

  • IGF-I gene therapy is a potentially effective treatment for prolactinomas.
  • Bioactive peptide gene delivery represents a novel therapeutic strategy for pituitary tumors.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...